ArticleCancers2020
Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma.Endocrine oncology (Bristol, England) · 2026Article
- Current evidence across the treatment spectrum of adrenocortical carcinoma: a comprehensive scoping review.Endocrine oncology (Bristol, England) · 2026Article
- Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell Model.Current oncology (Toronto, Ont.) · 2025Article
- Extraordinary Response to Mitotane Monotherapy in Advanced Aggressive Adrenocortical Carcinoma.JCEM case reports · 2025Article
- Multidisciplinary Tumor Board Evaluation of Pediatric Patients with Adrenocortical Tumors Across Seven International Centers.Cancers · 2025Article
- Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.Journal of endocrinological investigation · 2025Article
- Prolonged Mitotane Administration in Metastatic Adrenocortical Carcinoma With Over a Decade of Survival: A Case Series.Case reports in endocrinology · 2025Article
- A review of mitotane in the management of adrenocortical cancer.The oncologist · 2024Review
- Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.Current oncology reports · 2024Review
- Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.Frontiers in endocrinology · 2024Article
- Early Detection of Recurrence and Progress Using Serum Steroid Profiling by LC-MS/MS in Patients with Adrenocortical Carcinoma.Metabolites · 2023Article
- Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma.Endocrine-related cancer · 2023Article
- Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy.Frontiers in endocrinology · 2023Article
- Review
- Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.Biomedicines · 2022Article
- Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.Frontiers in endocrinology · 2022Article
- The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma.Frontiers in oncology · 2022Article
- Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies.Cancers · 2021Review
- The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.European journal of drug metabolism and pharmacokinetics · 2021Review
- Adrenocortical Carcinoma.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 1 country.
Soraya PuglisiInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0000-0002-2883-6139
Anna CalabreseInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.
Vittoria BasileInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.
Filippo CeccatoEndocrinology Unit, Department of Medicine DIMED, University-Hospital of Padua, 35128 Padua, Italy.ORCID 0000-0003-1456-8716
Carla ScaroniEndocrinology Unit, Department of Medicine DIMED, University-Hospital of Padua, 35128 Padua, Italy.
Barbara AltieriDivision of Endocrinology and Metabolic Diseases, University-Hospital Gemelli, IRCSS, Catholic University of the Sacred Heart, 00168 Rome, Italy.ORCID 0000-0003-2616-3249
Silvia Della CasaDivision of Endocrinology and Metabolic Diseases, University-Hospital Gemelli, IRCSS, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Paola LoliEndocrinology, Hospital Niguarda Ca' Granda, 20121 Milan, Italy.
Rosario PivonelloDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131 Naples, Italy.ORCID 0000-0002-9632-1348
Maria Cristina De MartinoDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131 Naples, Italy.ORCID 0000-0003-3354-009X
Letizia CanuEndocrinology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-4995-8108
Marco RussoEndocrinology Division, Department of Clinical and Experimental Medicine, ARNAS Garibaldi, University of Catania, 95122 Catania, Italy.ORCID 0000-0001-5151-9417
Giuseppe BadalamentiDepartment of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy.
Massimo TorlontanoUnit of Endocrinology, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
Antonio StiglianoEndocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy.
Francesco FerraùDepartment of Human Pathology of Adulthood and Childhood 'G. Barresi', University of Messina, 98125 Messina, Italy.
Giorgio ArnaldiDivision of Endocrinology, Department of Clinical and Molecular Sciences (DISCLIMO), Polytechnic University of Marche, 60121 Ancona, Italy.ORCID 0000-0002-6204-3423
Laura SabaInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.
Alessandra QuirinoInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.
Paola PerottiInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.
Paola BerchiallaStatistical Unit, Department of Clinical and Biological Sciences, Orbassano, University of Turin, 10143 Orbassano, Italy.ORCID 0000-0001-5835-5638
Massimo TerzoloInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, 10043 Turin, Italy.ORCID 0000-0002-4171-2851
Ospedale San Luigi Gonzaga · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Naples Federico II · ITUniversity of Padua · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITCasa Sollievo della Sofferenza · ITSapienza University of Rome · ITUniversity of Catania · ITUniversity of Florence · ITUniversity of Messina · ITUniversity of Palermo · ITUniversity of Turin · IT
Funding
Associazione Italiana per la Ricerca sul Cancro IG17678
Abstract
Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for ≥3 months, with ≥3 measurements of plasma mitotane reported in the Lysosafe Online
Indexed as
adrenal cancermitotaneprognosisrecurrencesurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.